Supreme Court rules human genes cannot be patented
Myriad Genetics, the company at the center of a Supreme Court decision saying human genes cannot be patented,
Investors' initial positive feelings about having the Supreme Court ruling behind them might be fleeting, says Daniel Leonard of Leerink Swann in a note to clients. Investors will soon focus on the fact that with more competition, Myriad's "dominant" market share "has nowhere to go but down," Leonard wrote. He points out that others rivals, including BRLI, University of Washington and Ambry Genetics have already stated they have plans to get into the business. Myriad's patents were due to expire in December 2015 regardless of the decision, Leonard says.